Skip to main content
Chison Medical Technologies Co.,Ltd. logo

Chison Medical Technologies Co.,Ltd. — Investor Relations & Filings

Ticker · 688358 ISIN · CNE1000076R4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2021-04-23 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688358

About Chison Medical Technologies Co.,Ltd.

https://www.chison.com/

Chison Medical Technologies Co.,Ltd. specializes in the research, development, and manufacturing of diagnostic ultrasound systems. The company offers a comprehensive portfolio of medical imaging solutions, including trolley-based color Doppler systems, portable ultrasound units, and specialized handheld devices. Its products integrate advanced imaging technologies such as 4D imaging, artificial intelligence-assisted diagnostics, and high-resolution transducers to support clinical applications in cardiology, obstetrics, gynecology, and point-of-care settings. Chison focuses on delivering high-performance diagnostic tools to healthcare providers, supported by a global network of research centers and distribution channels. The company emphasizes continuous innovation in digital signal processing and transducer technology to enhance diagnostic accuracy and clinical workflow efficiency.

Recent filings

Filing Released Lang Actions
祥生医疗独立董事关于第二届董事会第四次会议相关议案的独立意见
Board/Management Information Classification · 95% confidence The document is titled as an independent director's opinion on various proposals discussed at the company's second board's fourth meeting. It covers topics such as the 2021 remuneration plan for directors and senior management, appointment of the 2021 audit firm, 2020 profit distribution plan, use of raised funds, expected related party transactions, accounting policy changes, stock incentive plans, and other governance-related matters. The document is a detailed opinion and approval of board meeting proposals rather than a full financial report or earnings release. It does not contain comprehensive financial statements or quarterly results but focuses on board-level decisions and governance issues. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or opinions related to the board and senior management activities.
2021-04-23 Chinese
国金证券股份有限公司关于无锡祥生医疗科技股份有限公司2021年度日常关联交易额度预计事项的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed opinion and verification report from Guojin Securities Co., Ltd. regarding the 2021 annual expected daily related-party transaction amounts of Wuxi Xiangsheng Medical Technology Co., Ltd. It includes legal references, meeting dates, transaction amounts, related party details, and compliance with relevant laws and regulations. The document is not a full annual report or financial statement but rather a verification opinion related to regulatory compliance and related-party transactions. It is not a simple announcement or certification but a substantive report on a specific regulatory matter. This fits best under Regulatory Filings (RNS) as it is a compliance-related document that does not fit other specific categories like Annual Report or Audit Report.
2021-04-23 Chinese
祥生医疗关于独立董事公开征集委托投票权的公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a public announcement by an independent director of Wuxi Xiangsheng Medical Technology Co., Ltd. regarding the solicitation of proxy voting rights for the 2020 Annual General Meeting (AGM) scheduled on May 18, 2021. It details the proxy solicitation process, voting opinions, and instructions for shareholders to authorize the independent director to vote on their behalf on specific agenda items related to a restricted stock incentive plan. The document does not contain financial statements or results but is focused on the solicitation of voting rights for the AGM. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it is about the collection and announcement of proxy voting rights for shareholder voting at the AGM.
2021-04-23 Chinese
祥生医疗2021年限制性股票激励计划（草案）
Capital/Financing Update Classification · 95% confidence The document is a detailed plan regarding a 2021 restricted stock incentive plan for Wuxi Xiangsheng Medical Technology Co., Ltd. It includes legal references, definitions, purpose, management structure, scope of incentive recipients, stock allocation, vesting conditions, pricing, and procedures for implementation. The content is focused on the company's stock incentive plan, including issuance of restricted shares to employees and management, with detailed terms and conditions. This is not a financial report, earnings release, or regulatory filing about financial results. It is not a proxy solicitation or voting results announcement. It is a comprehensive disclosure about a capital/financing activity related to issuance of shares under a stock incentive plan. Therefore, the document fits best under Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content confirm it is the plan itself, not just an announcement of a report, so it is not RPA or RNS.
2021-04-23 Chinese
上海荣正投资咨询股份有限公司关于无锡祥生医疗科技股份有限公司2021年限制性股票激励计划（草案）之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is an Independent Financial Advisor Report regarding a 2021 restricted stock incentive plan for Wuxi Xiangsheng Medical Technology Co., Ltd. It includes detailed sections on definitions, statements, assumptions, main content of the stock incentive plan, scope and allocation of incentive targets, incentive methods, stock source and quantity, effective period, grant date, vesting arrangements, grant price and pricing method, grant and vesting conditions, and independent financial advisor opinions on compliance with laws and regulations, feasibility, scope and qualifications of incentive targets, equity grant limits, financial assistance, pricing methods, and impact on shareholders. The document is comprehensive, detailed, and contains substantive financial and operational analysis related to the stock incentive plan. It is not a brief announcement or a certification letter but a full advisory report with detailed financial and legal analysis. This type of document fits best under the category of Capital/Financing Update (CAP), as it relates to company fundraising, financing activities, or capital structure changes through a stock incentive plan.
2021-04-23 Chinese
上海市通力律师事务所关于无锡祥生医疗科技股份有限公司2021年限制性股票激励计划的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2021 restricted stock incentive plan of Wuxi Xiangsheng Medical Technology Co., Ltd. It discusses the legal compliance, procedures, qualifications, and disclosures related to the company's stock incentive plan. The document references relevant laws, regulations, and approvals from regulatory bodies such as the China Securities Regulatory Commission and the Shanghai Stock Exchange. It does not contain financial statements or audit results but focuses on the legal aspects of the stock incentive plan. This type of document is a legal opinion related to a capital/financing activity (stock incentive plan). Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-04-23 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.